Navigation Links
Odyssey Thera Granted U.S. Patent for Animal Imaging
Date:12/12/2007

SAN RAMON, Calif., Dec. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation Assays (PCA) in whole animals: applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy." This is the twelfth patent issued for Odyssey Thera's PCA process.

The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at Odyssey Thera to monitor drug response. The invention makes it possible to monitor specific biochemical parameters, including the extent and kinetics of drug target modulation, in a live subject.

"This patent extends our broad estate in drug discovery technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "One of the most challenging aspects of drug discovery is transitioning drug candidates from the test tube, to native targets in living cells, and from there to live subjects. With this invention, drug discovery and development are achieved with a single system that faithfully monitors the activity of a drug at each step." Dr. Westwick continues, "Whole animal studies using fluorescence or luminescence detection are widely used in the pharmaceutical industry, but strategies were needed to increase the scope of biochemical activities that can be tracked. The approaches described here will significantly increase the value of live subject imaging efforts."

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for chronic diseases. Odyssey Thera is leveraging its proprietary pathway-based approach and human cell models to optimize drug development for its own programs and for its premier pharmaceutical company partners.

To learn more about Odyssey Thera visit http://www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... , ... October 06, 2017 ... ... in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring ... kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using ...
(Date:10/6/2017)... ... 2017 , ... The HealthTech Venture Network (HTVN) is proud ... annual Conference where founders, investors, innovative practitioners and collaborators are invited to a ... early stage digital health and med tech companies. , This day-long event will ...
(Date:10/5/2017)... ... October 05, 2017 , ... LabRoots , the leading provider of educational ... is giving back to cancer research with a month-long promotion supporting the advancement of ... 31, shoppers can use promo code PinkRibbon to get 10 percent off their purchase ...
(Date:10/5/2017)... (PRWEB) , ... October 05, 2017 , ... ... to develop new applications of its Nanobind DNA/RNA extraction technology . Nanobind ... nanostructured silica on the surface and that can be used for a wide ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):